Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Copyright © 2019 Massachusetts Medical Society. BACKGROUND Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared fi...

Full description

Saved in:
Bibliographic Details
Main Authors: Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean Charles Soria
Format: Journal
Published: 2020
Subjects:
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85077224130&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/68504
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Internet

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85077224130&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/68504

Similar Items